National Trends in Use of and Spending on Oral Anticoagulants Among US Medicare Beneficiaries From 2011 to 2019

Authors:

Abstract
Direct oral anticoagulants (DOACs) reached the market in 2010 and are associated with lower bleeding risks and decreased monitoring compared with warfarin, but also higher costs.1 Early adoption of DOACs was brisk, but to our knowledge, little is known about recent patterns of oral anticoagulant use and how the introduction of competing DOACs have affected Medicare spending.2